Furthermore, the upregulation of TLR9 has been linked to specific breast cancer subtypes, particularly estrogen-receptor-negative (ER-) and triple-negative breast cancers (TNBC), which are known to exhibit a poorer prognosis and limited treatment options compared to hormone-receptor-positive tumors. Here, TLR9 is linked to triple-negative breast carcinoma.